Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Mapping of Adenosine Receptor Could Aid Drug Development

March 16, 2011 7:57 am | News | Comments

Researchers have solved the three-dimensional structure of a key biological receptor. The finding has the potential to speed drug discovery in many areas because it enables chemists to better examine and design molecules for use in experimental drugs.


Breakthrough for Rare Disease Linked to Diabetes

March 16, 2011 7:54 am | News | Comments

An international team of scientists have discovered new treatments for a rare and potentially lethal childhood disease that is the clinical opposite of diabetes mellitus.


Euthymics Begins EB-1010 Depression Study

March 16, 2011 7:46 am | News | Comments

Euthymics Bioscience, Inc. has initiated a phase 2b/3a study of its lead product candidate EB-1010, a novel serotonin-preferring triple reuptake inhibitor, for the treatment of major depressive disorder.


Promising Results in Nanodelivered Azide Study

March 16, 2011 7:39 am | News | Comments

Cornerstone Pharmaceuticals, Inc., a leader in cancer metabolism-based therapeutics, announced encouraging results of a preclinical toxicity study of azide drug-loaded Emulsiphan nano emulsions conducted with the National Cancer Institute.


Twin Cancer Agents Might Block Tumor Formation

March 16, 2011 7:33 am | News | Comments

A new study suggests that combining two experimental anticancer peptide agents might simultaneously block formation of new tumor blood vessels while also inhibiting the growth of tumor cells.


CPEX Pharma Offered Recapitalization

March 16, 2011 7:29 am | News | Comments

Specialty drug developer CPEX Pharmaceuticals Inc. said it received an unsolicited recapitalization offer from Mangrove Partners. CPEX said its board of directors will review the terms of the Mangrove offer as soon as practical.


Filtration System

March 16, 2011 7:27 am | Product Releases | Comments

EMD Millipore announced the introduction of the Samplicity Filtration System, an innovative new technology that provides a convenient, high throughput alternative to syringe-tip filters when preparing samples for chromatography.


LC-MS Software

March 16, 2011 7:24 am | Product Releases | Comments

Thermo Fisher Scientific Inc. announced new ExactFinder software for its Exactive benchtop LC-MS system. The new software offers clinical research laboratories a single streamlined data processing, review and reporting workflow.


Progenics Loses $18.8M in Q4

March 16, 2011 7:20 am | News | Comments

Progenics Pharmaceuticals Inc. reported a wider fourth-quarter loss compared to a year ago, when it received a large payment from a former partner.


Incyte Cancer Drug Meets Study Aims

March 16, 2011 7:19 am | News | Comments

Incyte Corp. said its main drug candidate met its goal in a second-late stage clinical trial, as the drug reduced swelling of the spleen in patients with a rare blood cancer.


Abbott CEO Sees Pay Drop

March 16, 2011 7:17 am | News | Comments

Drug and medical device maker Abbott Laboratories lowered Chief Executive Miles White's total compensation by 8 percent last year, as the company's its stock slid on concerns about future growth.


FDA Grants Lomitapide Orphan Drug Status

March 16, 2011 7:15 am | News | Comments

Aegerion Pharmaceuticals has received federal orphan drug status for its lead candidate, a treatment for people with severe lipid disorders. Orphan drug status is given to drugs that treat diseases or conditions that affect fewer than 200,000 people.


Amylin, Takeda Suspend Obesity Drug Trial

March 16, 2011 7:12 am | News | Comments

Amylin Pharmaceuticals Inc. and Takeda Pharmaceutical Co. Ltd. said they have suspended a mid-stage clinical trial of a combination obesity treatment to investigate a new "antibody-related laboratory finding" with one of the drugs.


Parkinson's Drug Could Be Boon for Impax

March 15, 2011 8:51 am | News | Comments

A potential Parkinson's disease treatment from Impax Laboratories Inc. could generate as much as $400 million in annual U.S. sales, according to a Collins Stewart analyst who raised her price target for the stock.


Pluristem And NYU Working on DFU Treatment

March 15, 2011 8:50 am | News | Comments

Pluristem Therapeutics, Inc. and New York University Medical Center announced the formation of a partnership to study the use of Pluristem’s proprietary placenta-derived PLX cells for the treatment of diabetic foot ulcers.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.